L-Glutamine Injection Solution

L-Glutamine Injection Solution

Available presentation(s): 30 mL. Verify the exact concentration and total active quantity on the prescription and dispensing label.

Introduction: L-glutamine is a conditionally essential amino acid during severe metabolic stress. Stand-alone compounded parenteral administration differs from licensed amino-acid nutrition products and has no general wellness regimen.

Dosage: No validated standard dose exists for the 30 mg/mL stand-alone injection. If used as part of clinical nutrition, dosing must be directed by a specialist dietitian/prescriber with total nitrogen, renal/hepatic function, route, dilution and compatibility considered.

Mechanisms of Action: Provides nitrogen and carbon for rapidly dividing cells, nucleotide synthesis and renal ammoniagenesis and serves as a precursor for glutathione.

Contraindications & Precautions: Use caution in severe hepatic impairment, hyperammonaemia, renal impairment and metabolic disorders. Monitor acid-base balance, ammonia and renal/hepatic function where relevant.

Interactions: Interactions are poorly characterised. Consider the complete parenteral nutrition regimen and avoid unvalidated admixtures.

Adverse Reactions / Side Effects: Nausea, fever, metabolic abnormalities, hyperammonaemia and infusion-site reactions are possible, particularly with inappropriate dosing or impaired clearance.

Pregnancy & Breastfeeding: Use only when clinically required as part of specialist nutrition support; evidence for elective supplementation is inadequate.

Storage: Store under the conditions stated on the Optimus dispensing label and product-specific worksheet. Protect from light where labelled. Do not freeze unless explicitly validated. Maintain cold chain if the label requires refrigeration. Do not use after the assigned beyond-use date or if there is visible particulate matter, precipitation, colour change, loss of container integrity or evidence of improper storage. Once entered, follow the validated in-use time; do not assume a compounded vial is multi-dose.

References

• New Zealand Formulary (NZF), current online edition; product-specific approved data sheets where available; USP Pharmaceutical Compounding—Sterile Preparations; and Optimus Healthcare validated formulation, sterility/endotoxin controls and assigned beyond-use date.
• US FDA. Compounding and the FDA: Questions and Answers. Updated 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers